- Home
- ZTR vs ZNTL Comparison
ZTR vs ZNTL Comparison
Compare ZTR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZTR | ZNTL |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.5M | 289.0M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZTR | ZNTL |
|---|---|---|
| Price | $5.96 | $2.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 122.5K | ★ 858.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.93 | $1.21 |
| 52 Week High | $7.11 | $6.95 |
Technical Indicators
Market Signals| Indicator | ZTR | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 18.13 | 21.81 |
| Support Level | N/A | $2.09 |
| Resistance Level | $6.89 | $2.69 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 3.75 | 4.77 |
Price Performance
Historical ComparisonAbout ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.